Since the use of hSpt16 RNAi as a therapeutic strategy to inhibit the FEAR pathway is likely to be technically challenging in vivo, we conducted a “proof of principle” series of cell culture experiments to determine if treatment with the small molecule FACT inhibitor, CBL0137, could similarly enhance VSVΔM51-GFP replication in restrictive cancer cell types. This evidence concerns the gene SUPT16H and cancer.